Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719598 | 0.86 | PDCD1LG2 (0.33) | CRHBPCRHR2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8737283 | 0.68 | LPAR1 (0.40) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19286071 | 0.66 | APOBEC3A (0.41) | SMN1; SMN2KDM4E | |
| SCHEMBL20719457 | 0.65 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21015040 | 0.64 | APOBEC3A (0.42) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20719527 | 0.64 | LPAR1 (0.34) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19578684 | 0.64 | APOBEC3A (0.39) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22541360 | 0.60 | APOBEC3A (0.38) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20719785 | 0.59 | PDCD1LG2 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL10442183 | 0.59 | GAA (0.39) | KDM4EALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CRHBP 1966/4885CRHR2 357/4885SMN1; SMN2 3697/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CRHBP 2102/4885CRHR2 481/4885SMN1; SMN2 3686/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CRHBP 1966/4885CRHR2 357/4885SMN1; SMN2 3697/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CRHBP 2102/4885CRHR2 481/4885SMN1; SMN2 3686/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CRHBP 2036/4885CRHR2 431/4885SMN1; SMN2 3825/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CRHBP 2036/4885CRHR2 431/4885SMN1; SMN2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.